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Abstract 18 
Inflammasomes are multimeric protein complex that assemble in the cytosol 19 
upon microbial infection or cellular stress. Upon activation, inflammasomes 20 
drive the maturation of proinflammatory cytokines interleukin (IL)-1 and IL-18, 21 
and also activate the pore-forming protein gasdermin D to initiate a form of lytic 22 
cell death known as ‘pyroptosis’. Pannexin-1 is channel-forming glycoprotein 23 
that promotes membrane permeability and ATP release during apoptosis; and 24 
was implicated in canonical NLRP3 or non-canonical inflammasome activation. 25 
Here, by utilising three different pannexin-1 channel inhibitors and two lines of 26 
Panx1–/– macrophages, we provide genetic and pharmacological evidence that 27 
pannexin-1 is dispensable for canonical or non-canonical inflammasome 28 
activation. Instead, we demonstrate that pannexin-1 cleavage and resulting 29 
channel activity during apoptosis promotes NLRP3 inflammasome activation.  30 
  31 
Introduction 32 
 33 
The innate immune system provides the first line of defence against microbial 34 
pathogens but also drives inflammatory diseases. Inflammasomes, multimeric 35 
protein complexes that assemble in the cytosol in response to infection or 36 
cellular stress, are now emerging as key molecular drivers of both processes 37 
[1]. The NLRP3 inflammasome comprises the NLRP3 sensor protein, the 38 
adaptor protein ASC and the protease caspase-1. NLRP3 is an unusual sensor 39 
protein because it has a unique ability to sense a wide variety of structurally-40 
unrelated molecules ranging from whole pathogens, bacterial toxins, ATP 41 
released from damaged cells, particulate crystals or misfolded protein 42 
aggregates such as α-synuclein generated during neurodegenerative disease 43 
[2]. The precise mechanism by which NLRP3 senses these structurally diverse 44 
agonists remains unclear, however, it appears that the vast majority of NLRP3 45 
agonists elicit a common potassium efflux stress pathway that is sensed by 46 
NLRP3 [3]. Upon activation, NLRP3 oligomerises and recruits the adaptor 47 
protein ASC into large filamentous structure called the ‘ASC speck’, which 48 
creates a multitude of binding sites for the caspase-1 zymogen [4, 5]. Caspase-49 
1 recruited within the inflammasome undergoes proximity-induced activation 50 
and autoprocessing to generate an active p33/p10 fragment, and is further 51 
processed to an inactive p20/p10 fragment that is released from the 52 
inflammasome [6]. Active caspase-1 cleaves the pore-forming protein 53 
gasdermin D (GSDMD) to induce a form of lytic cell death known as pyroptosis 54 
[7, 8]. In parallel, caspase-1 cleaves interleukin (IL)-1 family members such as 55 
pro-IL-1 and triggers IL-1 relocation to the plasma membrane to enable 56 
GSDMD-dependent and independent secretion [9-11].  57 
 58 
The non-canonical inflammasome pathway is activated by cytoplasmic 59 
lipopolysaccharide (LPS) from Gram-negative bacteria [12]. Unexpectedly, 60 
LPS sensing by the non-canonical inflammasome does not require a classical 61 
pattern recognition receptor. Instead, cytoplasmic LPS appears to directly bind 62 
the caspase recruitment domain (CARD) of caspase-11, triggering caspase-11 63 
oligomerization and activation [13]. In macrophages, active caspase-11 cleaves 64 
its substrate, GSDMD to trigger pyroptosis [7, 8], while in neutrophils, active 65 
GSDMD promotes plasma and nuclear membrane damage and the extrusion 66 
of neutrophil extracellular traps [14]. Of note, caspase-11 is unable to directly 67 
process pro-IL-1, but does so indirectly by triggering GSDMD pores, 68 
potassium efflux and NLRP3 inflammasome activation in a cell-intrinsic manner 69 
[7, 8, 12, 15]. 70 
 71 
Pannexin-1 is a channel-forming transmembrane protein with that is expressed 72 
in most cell types, including macrophages. Under resting state, the pannexin-1 73 
channel is autoinhibited by its cytoplasmic C-terminal tail. During apoptosis, 74 
effector caspase-3 and -7 cleave pannexin-1 at its C-terminus to promote 75 
pannexin-1 channel opening and drive membrane permeability [16, 17]. In 76 
agreement with this model, we recently demonstrate that pannexin-1 channels 77 
promote NLRP3 inflammasome assembly during apoptosis [18]. Interestingly, 78 
exposure of macrophages to pannexin-1 inhibitor carbenoxolone or the 79 
pannexin-1 inhibitory peptide 10PANX were reported to suppress canonical 80 
NLRP3 inflammasome activation [19-21]. More recently, pannexin-1 channel 81 
was also implicated to promote pyroptosis and NLRP3 activation following the 82 
assembly of the non-canonical inflammasome [22]. However, this finding is at 83 
odds with the observation that caspase-11 drives NLRP3 inflammasome 84 
activation through GSDMD pores [7, 8]. Whether pannexin-1 is required for 85 
optimal GSDMD processing and NLRP3 inflammasome activation after 86 
cytoplasmic LPS recognition is unclear and a focus of this study. Here, by using 87 
two independent lines of Panx1-deficient cells, we provide genetic evidence 88 
that pannexin-1 is only required for NLRP3 assembly during apoptosis but is 89 
dispensable for canonical NLRP3 or non-canonical inflammasome activation. 90 
 91 
Results and discussion 92 
 93 
Pannexin-1 channel activity is required for NLRP3 inflammasome activation 94 
during apoptosis 95 
 96 
The requirement for pannexin-1 in canonical and non-canonical inflammasome 97 
activation is controversial [19-21, 23]. To examine the function of pannexin-1 in 98 
inflammasome activation, we first tested probenecid, trovafloxacin and 99 
spironolactone, three well-established pharmacological inhibitors of pannexin-100 
1 channel activity [24-26]. We recently demonstrated that pannexin-1 promotes 101 
potassium efflux and NLRP3 inflammasome activation during intrinsic and 102 
extrinsic apoptosis in macrophages [18]. In agreement with that, we observed 103 
robust processing of full length pannexin-1 into the cleaved p19 fragment when 104 
bone marrow-derived macrophages (BMDMs) were exposed to the BH3-105 
mimetic ABT-737 and MCL1 inhibitor S63845 to induce intrinsic apoptosis (Fig. 106 
1A). Probenecid, trovafloxacin and spironolactone had little to no effect on 107 
pannexin-1 cleavage, but completely abrogated caspase-1 processing in 108 
apoptotic BMDMs, indicating that pannexin-1 channel activity and resultant 109 
cellular permeability drives NLRP3 inflammasome assembly during apoptosis 110 
(Fig. 1A). Next, we investigated whether pannexin-1 inhibitors similarly block 111 
IL-1 secretion during intrinsic apoptosis. For this, we primed BMDMs with LPS 112 
for 3 h to induce pro-IL-1 expression, and stimulated the cells for another 16 113 
h with the ABT-737 and S63845 for to induce intrinsic apoptosis in the presence 114 
of absence of pannexin-1 inhibitors. Pannexin-1 inhibitors had little to no effect 115 
on macrophage cytotoxicity (Fig. 1B). Consistent with our recent finding [18], 116 
we observed that IL-1 secretion was significantly reduced in apoptotic Panx1–117 
/– macrophages compared to WT cells. In agreement with this, the pannexin-1 118 
inhibitor, spironolactone similarly reduced IL-1 secretion in apoptotic wild type 119 
macrophages (Fig. 1C). Of note, spironolactone also further reduced IL-1 120 
secretion in Panx1–/– BMDMs, indicating that spironolactone additionally 121 
inhibits IL-1 secretion through pannexin-1-independent mechanisms. 122 
Surprisingly, while probenecid and trovafloxacin blocked caspase-1 processing 123 
in unprimed apoptotic macrophages over a 5 h period (Fig. 1A), they were 124 
ineffective in blocking IL-1 secretion in LPS-primed apoptotic macrophages 125 
over 16 h (Fig. 1C). Next, we investigated if pannexin-1 channel activity 126 
similarly promotes NLRP3 activation during extrinsic apoptosis. Indeed, 127 
probenecid, trovafloxacin and spironolactone similarly reduced caspase-1 128 
cleavage but not pannexin-1 processing when BMDMs were treated with TNF 129 
and the SMAC-mimetic AZD5582 to trigger extrinsic apoptosis (Fig. 1D). Taken 130 
together, these data indicate that during apoptosis, pannexin-1 channel 131 
opening promotes NLRP3 inflammasome activation, most likely by triggering 132 
membrane permeability. 133 
 134 
Pannexin-1 is not required for canonical NLRP3 inflammasome activation 135 
 136 
Having established that pannexin-1 channel inhibitors suppress NLRP3 137 
activation during apoptosis (Fig. 1A, D), we next investigated the function of 138 
pannexin-1 in canonical NLRP3 inflammasome signalling. For this, we primed 139 
wild type (WT) or Panx1–/– BMDMs with LPS for 4 h to induce NLRP3 and pro-140 
IL-1 expression, and stimulated the cells with the soluble NLRP3 agonists 141 
nigericin and ATP, or the insoluble particulate agonist monosodium urate 142 
(MSU). In contrast to apoptotic triggers (Fig. 1A, D), probenecid, trovafloxacin 143 
and spironolactone had no effect on caspase-1 processing in nigericin-144 
stimulated macrophages (Fig. 2A). In agreement with that, cleavage of the 145 
caspase-1 substrate GSDMD was unaffected by pannexin-1 inhibitors, 146 
although a minor reduction in pro-IL-1 processing was consistently observed 147 
(Fig. 2A). Importantly, caspase-1 processing and cleavage of the caspase-1 148 
substrates, pro-IL-1 and GSDMD were comparable between WT and Panx1–149 
/– BMDMs (Fig. 2A, Supplementary Fig. 1A). IL-1 secretion and macrophage 150 
pyroptosis, as measured by lactate dehydrogenase (LDH) release, were similar 151 
between WT and Panx1–/– BMDMs (Fig. 2B-C, Supplementary Fig. 1B). In 152 
contrast, nigericin-induced IL-1 secretion and pyroptosis were completely 153 
dependent on GSDMD (Fig. 2D-E), consistent with previous reports (ref). Next, 154 
we investigated whether pannexin-1 is required for ATP-induced NLRP3 155 
inflammasome activation. Consistent with before, we observed comparable 156 
levels of caspase-1, pro-IL-1 and GSDMD processing between WT and 157 
Panx1–/– BMDMs upon ATP stimulation (Fig. 2D, Supplementary Fig. 1A). As 158 
expected, IL-1  secretion and pyroptosis were similar between ATP-stimulated 159 
WT and Panx1–/– BMDMs, but completely abrogated in Gsdmd–/– cells (Fig. 2G-160 
J, Supplementary Fig. 1B). Interestingly, probenecid but not trovafloxacin or 161 
spironolactone reduced caspase-1 processing and cleavage of caspase-1 162 
substrates in both WT and Panx1–/– BMDM, indicating that probenecid inhibits 163 
ATP-induced inflammasome activation in a pannexin-1-independent manner. 164 
In support of this, a recent study revealed that probenecid directly blocks the 165 
ATP-gated ion channel P2X7 [27]. Next, we investigated whether pannexin-1 166 
is required for NLRP3 inflammasome upon exposure to the particulate agonist, 167 
MSU. In agreement with our findings with soluble NLRP3 agonists, we found 168 
that pharmacological or genetic blockade of pannexin-1 had no impact on 169 
caspase-1, pro-IL-1 and GSDMD processing in BMDMs following MSU 170 
stimulation (Fig. 2K). In line with that, IL-1  secretion and pyroptosis were 171 
similarly unaffected by Panx1-deficiency (Fig. 2L-M). Consistent with a recent 172 
report [28], we observed that MSU-induced cell lysis and IL-1  secretion 173 
occurs independently of the pyroptotic effector GSDMD (Fig. 2N-O). Lastly, we 174 
examined pannexin-1 cleavage following canonical NLRP3 inflammasome 175 
activation. In line with our earlier observations (Fig. 2A-C, F-H, K-M), we found 176 
no evidence of pannexin-1 cleavage during canonical inflammasome activation, 177 
although treatment with ABT-737/S63845 to trigger apoptosis induced robust 178 
pannexin-1 cleavage in macrophages as expected (Fig. 2P). Taken together, 179 
these data indicate that while pannexin-1 is required for driving NLRP3 180 
inflammasome assembly during apoptosis, it is dispensable for canonical 181 
NLRP3 inflammasome activation in macrophages. 182 
 183 
GSDMD but not pannexin-1 promotes cell death and NLRP3 assembly 184 
following non-canonical inflammasome activation 185 
 186 
Two recent landmark studies revealed that caspase-11 cleaves its substrate 187 
GSDMD to drive pyroptosis, potassium efflux and NLRP3 activation [7, 8]. By 188 
contrast, another study proposed that caspase-11-dependent pyroptosis and 189 
NLRP3 assembly requires pannexin-1 channel activity [22], raising the 190 
possibility that pannexin-1 channels potentiate GSDMD pore activity. To 191 
investigate whether GSDMD processing, cell death or NLRP3 inflammasome 192 
activation require pannexin-1 channel activity, we prepared WT and Gsdmd–/– 193 
BMDMs and activated the non-canonical inflammasome by LPS transfection in 194 
the presence or absence of the pannexin-1 inhibitors probenecid, trovafloxacin 195 
and spironolactone. In agreement with previous reports [8, 12], we observed 196 
that cytoplasmic LPS induced cleavage of the caspase-11 substrate GSDMD 197 
into the active p30 fragment and resulted in pyroptosis (Fig. 3A-B). In addition, 198 
GSDMD was required to drive caspase-1 processing, pro-IL-1 maturation and 199 
secretion (Fig. 3A, C). Exposure of LPS-transfected BMDMs to probenecid, 200 
trovafloxacin and spironolactone had no effect on GSDMD, caspase-1 and pro-201 
IL-1 processing (Fig. 3A), while all three pannexin-1 inhibitors suppressed 202 
caspase-1 processing in apoptotic macrophages (Fig. 1A, D). Next, we 203 
compared LPS transfection in WT and Panx1–/– BMDMs. In line with our 204 
inhibitor data, we observed comparable levels of GSDMD, caspase-1 and pro-205 
IL-1 processing in WT and Panx1–/– BMDMs (Fig. 3C, Supplementary Fig. 206 
1C). And as expected, IL-1 secretion and pyroptosis were unaffected by 207 
Panx1-deficiency compared to WT BMDM (Fig. 3D-E, Supplementary Fig. 208 
1D-E). However, all three pannexin-1 inhibitors triggered a mild, but non-209 
significant reduction in IL-1 secretion in both WT and Panx1–/– macrophages 210 
(Fig. 3F). Lastly, we investigated the status of pannexin-1 cleavage upon non-211 
canonical inflammasome activation. In agreement with our observation that 212 
pannexin-1 is dispensable for non-canonical inflammasome signalling (Fig. 3D-213 
F), we did not find any evidence of pannexin-1 cleavage during non-canonical 214 
inflammasome activation; in contrast, full length pannexin-1 was completely 215 
converted into the cleaved p19 fragment in apoptotic macrophages (Fig. 3H). 216 
Taken together, our data support the conclusion that non-canonical 217 
inflammasome drives pyroptosis, NLRP3 activation and IL-1 secretion through 218 
GSDMD pores but not pannexin-1 channels. 219 
 220 
Concluding remarks 221 
 222 
Pannexin-1 is a channel-forming transmembrane protein with that is widely 223 
expressed in most cell types, including in transformed cells [29]. Our finding 224 
that pannexin-1 channel opening during apoptosis promotes NLRP3 225 
inflammasome activation has major clinical relevance, especially under 226 
conditions where IL-1 signalling has been implicated to impair tumour 227 
clearance [30]. While our study only examined apoptosis induced by SMAC-228 
mimetic, BH3-mimetic and MCL1 inhibitor, it is likely that other commonly used 229 
apoptosis-inducing chemotherapies such as cisplatin and doxorubicin would 230 
similarly activate the NLRP3 inflammasome through pannexin-1 channels. The 231 
pannexin-1 channel inhibitor spironolactone is an inexpensive, orally-available 232 
drug that is already approved for human use [26]. Therefore, spironolactone 233 
could potentially offer rapid clinical translation and be administered in 234 
combination with standard chemotherapeutics to reduce NLRP3 and IL-235 
1 signalling to promote tumour clearance.  236 
 237 
Pharmacological pannexin-1 inhibitor or siRNA knockdown of pannexin-1 were 238 
reported to suppress canonical NLRP3 inflammasome activation [19-21]. 239 
Based on these observations, it was proposed that pannexin-1 channels 240 
promote NLRP3 inflammasome assembly. However, this concept was 241 
subsequently challenged as NLRP3 inflammasome signalling were found to be 242 
similar between WT and Panx1–/– BMDMs [23]. By using two independent lines 243 
of Panx1–/– BMDMs and three different pannexin-1 channel inhibitors, we 244 
confirmed previous reports and conclude that pannexin-1 is indeed dispensable 245 
for canonical NLRP3 inflammasome activation in murine macrophages.  246 
 247 
Recognition of cytosolic Gram-negative bacteria by caspase-11 promotes 248 
pyroptosis and NLRP3 inflammasome activation, and this pathway confers 249 
susceptibility to murine models of endotoxin shock (ref). However, the 250 
mechanism by which caspase-11 drives cell death and NLRP3 activation 251 
remains debated. While two landmark studies identified that caspase-11 252 
cleaves GSDMD to trigger pyroptosis and NLRP3 activation [7, 8], another 253 
study proposed that caspase-11-dependent pyroptosis and NLRP3 activation 254 
requires the membrane glycoprotein pannexin-1 [22]. In this model, the authors 255 
proposed that caspase-11 cleaves pannexin-1 to drive membrane permeability 256 
and NLRP3 inflammasome activation, while pannexin-1-dependent ATP 257 
release promotes pyroptosis via engagement of the purinergic receptor P2X7. 258 
Here, by using three different pannexin-1 channel inhibitors and 2 lines of 259 
Panx1–/– BMDMs, we provide evidence that pannexin-1 is not processed upon 260 
non-canonical inflammasome activation and demonstrate that pannexin-1 is 261 
dispensable for non-canonical inflammasome signalling in BMDM. In contrast, 262 
our study supports the conclusion that active caspase-11 promotes cell lysis 263 
and NLRP3 activation via GSDMD pores. While the report from Yang et al. and 264 
our study both utilised Panx1–/– lines generated from C57BL/6 background, it 265 
remains possible, but unlikely, that passenger mutation and genetic variation 266 
between the Panx1–/– lines might influence the outcome of the study. This is 267 
because Panx1–/– BMDMs used in the study of Yang et. al expressed 268 
comparable levels of caspase-11 compared to WT cells; and are also likely to 269 
express normal levels of GSDMD since Panx1-deficiency did not affect 270 
pyroptosis upon NLRP3 and AIM2 activation in that study (ref). While we 271 
provide clear evidence that pannexin-1 is dispensable for non-canonical 272 
inflammasome signalling in BMDMs, at this moment, we cannot rule out the 273 
possibility that that pannexin-1 may indeed confer susceptibility to murine 274 
models of endotoxin shock in vivo. Since apoptotic caspases contribute to 275 
endotoxin-induced lethality (ref), it is tempting to speculate that pannexin-1 may 276 
potentially contribute to lethality by promoting NLRP3 activation, pyroptosis and 277 
IL-1 secretion in apoptotic cells (ref). Future studies should confirm the role of 278 
pannexin-1 in endotoxin-induced lethality and explore the therapeutic function 279 





  285 
Materials and methods 286 
 287 
Mice 288 
C57BL/6 and Gsdmd–/– mice were housed in specific-pathogen free facilities in 289 
the University of Lausanne. Panx1–/– were previously described [31, 32] and 290 
kindly provided by Prof. Marc Chanson and Prof. Nathalie Rouach.  291 
 292 
Cell culture 293 
Murine bone marrow-derived macrophages (BMDM) were prepared by 294 
differentiating bone marrow progenitor cells for 7 days in DMEM (Gibco) 295 
supplemented with 20% MCSF (3T3 supernatant), 10% heat-inactivated FCS 296 
(Bioconcept), 10 mM HEPES (Bioconcept), penicillin/streptomycin 297 
(Bioconcept) and non-essential amino acids (Gibco). Inflammasome and 298 
apoptosis assays were performed on mature BMDMs on day 7–9 of 299 
differentiation. All WT versus Panx1–/– data presented in the main manuscript 300 
were generated using Panx1–/– and WT control BMDM provided by Prof Marc 301 
Chanson [32], while all WT versus Panx1–/– data in the supplementary data 302 
were generated using Panx1–/– and WT controls provided by Prof Nathalie 303 
Rouach [31]. 304 
 305 
Apoptosis assay 306 
BMDMs were plated in 96-well plates at a density of 5 × 104 cells per well in 307 
complete media a day prior to stimulation. BMDMs were stimulated with a 308 
combination of ABT-737 and S63845 (all 0.5 μM; Selleckchem) or a 309 
combination of recombinant murine TNF (100 ng/ml; Enzo) and the SMAC-310 
mimetic AZD5582 (0.5 μM; Selleckchem) in Opti-MEM for 5 h to induce intrinsic 311 
or extrinsic apoptosis respectively. To measure IL-1 secretion, BMDMs were 312 
primed for 4 h in Opti-MEM and stimulated with ABT-737 and S63845 (all 1 μM; 313 
Selleckchem) for 16 h. Where indicated, cells were treated with probenecid (1 314 
mM; Sigma), trovafloxacin (10 μM; Sigma) or spironolactone (20 μM; Sigma) 315 
30 min prior to cell stimulation. 316 
 317 
Inflammasome assay 318 
BMDMs were plated in 96-well plates at a density of 5 × 104 cells per well in 319 
complete media a day prior to stimulation. To activate the canonical NLRP3 320 
inflammasome, cells were primed with ultrapure E. coli 055:B5 LPS (100 ng/ml; 321 
InvivoGen) for 4 h in Opti-MEM and stimulated with nigericin (5 μM; Invivogen) 322 
or ATP (2.5 mM; Sigma) for 90 min, or MSU (150 μg/ml; Invivogen) for 4 h. To 323 
activate the non-canonical inflammasome, cells were primed with Pam3CSK4 324 
(1 μg/ml; Invivogen) for 4 h in Opti-MEM and transfected with ultrapure E. coli 325 
0111:B4 LPS (2 μg/ml) using 0.25% Fugene HD (Promega) and centrifuged for 326 
500 g for 10 min at 37oC. BMDMs were harvested 16 h post LPS transfection. 327 
Where indicated, cells were treated with probenecid (1 mM; Sigma), 328 
trovafloxacin (10 μM; Sigma) or spironolactone (20 μM; Sigma) at the last 20–329 
30 min of priming. 330 
 331 
Immunoblotting 332 
Cell extracts were lysed in in boiling lysis buffer (66 mM Tris–Cl pH 7.4, 2% 333 
SDS, 10 mM DTT, 1x NuPage LDS sample buffer; Thermo Fisher) and 334 
resuspended with methanol/chloroform-precipitated supernatant. Mixed 335 
supernatant and extracts were separated on 14% polyacrylamide gels and 336 
transferred onto nitrocellulose membrane using Trans-blot Turbo (Bio-rad). 337 
Antibodies for immunoblot were against caspase-1 p20 (casper-1; Adipogen; 338 
1:1000), GSDMD (EPR19828; Abcam; 1:1000), pro-IL-1 (AF-401-NA, R&D; 339 
1:1000), pannexin-1 (D9M1C; Cell Signaling; 1:1000) and alpha-tubulin (DM1A; 340 
Abcam; 1:5000). 341 
 342 
LDH assay  343 
Lactate dehydrogenase (LDH) release into the cell culture supernatant was 344 
quantified using the TaKaRa LDH cytotoxicity detection kit (Clontech) according 345 
to the manufacture’s protocol. 346 
 347 
IL-1 ELISA 348 
IL-1 release into the cell culture supernatant was quantified using the mouse 349 
IL-1 beta DuoSet ELISA Kit (R&D systems) according to the manufacture’s 350 
protocol. 351 
 352 
Statistical analyses 353 
Statistical analyses were performed using GraphPad Prism 7 software. All data 354 
sets were analysed using the parametric t-test. Data were considered 355 
significant when *P ≤ 0.05, **P ≤ 0.01. 356 
 357 
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  493 
Figure legends 494 
 495 
 496 
Figure 1. Channel activity of pannexin-1 is required for NLRP3 497 
inflammasome activation during apoptosis. (A) BMDMs were treated 498 
stimulated with ABT-737 (0.5 M) and S63845 (0.5 M) for 5 h to induce 499 
intrinsic apoptosis. (B-C) BMDMs were primed with LPS (100 ng/ml) for 3 h and 500 
stimulated with ABT-737 (1 M) and S63845 (1 M) for 16 h. (D) BMDMs were 501 
stimulated with TNF (100 ng/ml) and AZD8882 (0.5 M) for 5 h to induce 502 
intrinsic apoptosis.  Where indicated, pannexin-1 channel inhibitors probenecid 503 
(1 mM), trovafloxacin (10 M) and spironolactone (20 M) were added 30 min 504 
prior to cell stimulation. (B, C) Data are mean ± S.E.M of pooled data from 3 505 
independent experiments. Data were considered significant when *P < 0.05, 506 
**P < 0.01. Immunoblots show mixed supernatant and cell extracts and are 507 





Figure 2. Pannexin-1 is dispensable for canonical NLRP3 inflammasome 513 
activation. (A-P) BMDMs were primed with 100 ng/ml ultrapure LPS for 4 h 514 
and stimulated with nigericin (0.5 M; 90 min), ATP (2.5 mM; 90 min) or MSU 515 
(150 g/ml; 4 h), or stimulated with ABT-737 (0.5 M) and S63845 (0.5 M) for 516 
5 h. Where indicated, pannexin-1 channel inhibitors probenecid (1 mM), 517 
trovafloxacin (10 M) and spironolactone (20 M) were added 30 min prior to 518 
cell stimulation. (A, F, K, P) Mixed supernatant and cell extracts were examined 519 
by immunoblotting and are representative of at 2-3 independent experiments. 520 
Data are mean ± S.D. of triplicate cell stimulation, representative of 3 (B, C, G, 521 
H, L, M) or 2 (N, O) independent experiments; (D, E, I, J) data are mean ± 522 
S.E.M of pooled data from 3 independent experiments. Data were considered 523 
significant when *P < 0.05, **P < 0.01. 524 
 525 
 526 
Figure 3. Non-canonical inflammasome drives pyroptosis and NLRP3 527 
activation via GSDMD but not pannexin-1. (A-G) BMDMs were primed with 528 
1 g/ml Pam3CSK4 for 4 h and transfected with 2 g/ml ultrapure 0111:B4 LPS 529 
using Fugene for 16 h, or treated stimulated with ABT-737 (0.5 M) and S63845 530 
(0.5 M) for 5 h. (A, D, G) Mixed supernatant and cell extracts were examined 531 
by immunoblotting and are representative of at 2-3 independent experiments. 532 
(B-C) Data are mean ± S.E.M of pooled data from 3 independent experiments 533 
or (E-F) mean ±  S.D of triplicate cell stimulation representative of 3 534 
independent experiments. Data were considered significant when *P < 0.05, 535 





Supplementary Figure 1. Pannexin-1 is dispensable for canonical or non-541 
canonical inflammasome signalling. (A-B) BMDMs were primed with 100 542 
ng/ml ultrapure LPS for 4 h and stimulated with nigericin (0.5 M; 90 min) or 543 
ATP (2.5 mM; 90 min). (C-E) BMDMs were primed with 1 g/ml Pam3CSK4 for 544 
4 h and transfected with 2 g/ml ultrapure 0111:B4 LPS using Fugene for 16 h. 545 
(B, D, E) Data are mean ± S.D of triplicate cell stimulation representative of 2-546 
3 independent experiments. 547 
